Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Norikazu Kikuchi"'
Autor:
Sakae Fukushima, Manami Oishi, Hiroya Aso, Kifumi Arai, Yuuki Sasaki, Naohiro Tochikura, Susumu Ootsuka, Noriyasu Fukuoka, Nobuhiro Ooba, Norikazu Kikuchi
Publikováno v:
European Journal of Hospital Pharmacy; Jul2023, Vol. 30 Issue 4, p208-213, 6p
Autor:
Toru Imai, Nobutaka Chiba, Atsushi Sakurai, Norikazu Kikuchi, Shinji Hidaka, Masao Sekimoto, Mitsumasa Hata
Publikováno v:
Journal of Clinical Pharmacy and Therapeutics
What is known and objective Favipiravir is a promising treatment candidate for managing coronavirus disease 2019 (COVID‐19). Warfarin has many drug interactions, but no interactions with favipiravir have been reported. Case summary Our patient was
Autor:
Masatoshi Hayasaka, Hideki Otsuka, Daisuke Tsutsumi, Shunsuke Iizuka, Tatsuya Hayama, Kenichi Sakurai, Yumi Kabaya, Norikazu Kikuchi
Publikováno v:
Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences). 45:485-490
Autor:
Takahiro Nakayama, Makoto Makishima, Naohiro Tochikura, Yoshikazu Yoshida, So Iwabuchi, Takako Sakaue, Norikazu Kikuchi, Toru Imai, Masao Sekimoto, Shinichiro Suzuki, Masayuki Chuma, Tsukasa Kuwana, Kosaku Kinoshita, Nami Sawada
Publikováno v:
European Journal of Clinical Pharmacology. 75:929-937
It is important to accurately estimate accurate vancomycin (VCM) clearance (CLvcm) for appropriate VCM dosing in the treatment of patients with sepsis. However, the pathophysiology of sepsis can make CLvcm prediction less accurate. Clearance of hydro
Autor:
Norikazu Kikuchi, Yoshikazu Yoshida, Naohiro Tochikura, Nami Sawada, Kosaku Kinoshita, Shinichiro Suzuki, Toru Imai, Tsukasa Kuwana, Masayuki Chuma, Makoto Makishima
Publikováno v:
Proceedings for Annual Meeting of The Japanese Pharmacological Society. :PO2-14
Autor:
Yuuki Sasaki, Susumu Ootsuka, Norikazu Kikuchi, Kifumi Arai, Naohiro Tochikura, Manami Oishi, Hiroya Aso, Sakae Fukushima, Noriyasu Fukuoka, Nobuhiro Ooba
Publikováno v:
European Journal of Hospital Pharmacy. :ejhpharm-2021
Objective To examine the effect of angiotensin II receptor blocker (ARB) treatment on serum potassium level and hyperkalaemia risk in a clinical setting with inpatients and outpatients using calcium channel blockers (CCBs) as a reference standard. Me
Autor:
Yoshikazu Yoshida, Norikazu Kikuchi, Katsuyuki Hazama, Shinji Hidaka, Toru Imai, Shinichiro Suzuki
Publikováno v:
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan. 138(7)
The Japanese Adverse Drug Event Report (JADER) database was used to examine the risk of delirium and the time of its onset with various hypnotics, including 10 benzodiazepines (BZDs), 3 non-benzodiazepines (non-BZDs), 1 melatonin receptor agonist (MR
Autor:
Naohiro Tochikura, Yoshikazu Yoshida, Toru Imai, Makoto Makishima, Kosaku Kinoshita, Masayuki Chuma, Norikazu Kikuchi, Takako Sakaue, Morio Kaburaki
Publikováno v:
Clinical therapeutics. 38(12)
Vancomycin (VCM) is used in the treatment of methicillin-resistant Staphylococcus aureus infection. The dosage of VCM must be adjusted by using therapeutic drug monitoring because of the drug's narrow therapeutic concentration window. Although optima
Autor:
Fumiyoshi Ishii, Kiyoshi Mihara, Taeko Kitano, Norikazu Kikuchi, Hiroyasu Ogata, Mizue Makimura, Yutaka Kubota, Keiko Ohno
Publikováno v:
YAKUGAKU ZASSHI. 124:1-11
We performed a systematic review of the effectiveness of anti-emetics for prophylaxis of cisplatin-induced delayed emesis using meta-analysis. We selected 12 reports of randomized controlled trials from MEDLINE (1966-2003. 4) and The Cochrane Library
Autor:
Masayuki Chuma, Makoto Makishima, Toru Imai, Naohiro Tochikura, Shinichiro Suzuki, Tsukasa Kuwana, Nami Sawada, Tomohide Komatsu, Takako Sakaue, Norikazu Kikuchi, Yoshikazu Yoshida, Kosaku Kinoshita
Publikováno v:
Therapeutic Drug Monitoring; Feb2018, Vol. 40 Issue 1, p109-114, 6p